🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At the 2025 Advocate Leadership Summit, we will continue to build on the strengths of the tireless and talented advocates who will help NBCC achieve our mission to end breast cancer for everyone. Register today! nbcc.info/25Summit

As the Trump administration makes significant cuts to programs that impact all of us, we want to hear from you: Are people in your community experiencing issues accessing care or funding? Please share your stories with us to inform future advocacy efforts. nbcc.info/FundingSurvey

Take action today and urge your representative to cosponsor the Metastatic Breast Cancer Access to Care Act! nbcc.info/TakeAction

Stand up for breast cancer priorities! On our #LobbyDay, join NBCC advocates, members of Congress, and others to support science, research, health care, and policies to end breast cancer at the US Capitol Grounds on May 6, at 9am! nbcc.info/BreastCancerRa…

"The DOD program was developed in order to be innovative… From our perspective, we feel like the breakthrough treatment that’s going to ultimately end breast cancer—it’s most likely to come out of the DOD program" - NBCC’s MelanieNBCC in The Cancer Letter stopbreastcancer.org/in-the-cancer-…

Unite to end breast cancer and RALLY with us on #LobbyDay after the #NBCCSummit! We're loud and clear that breast cancer research and healthcare must remain a top priority for Congress and this administration! #NBCContheHill nbcc.info/BreastCancerRa…

Yesterday, NBCC supporters gathered in New York to honor the legacy of Carol Vance Wall; two-time breast cancer survivor Linda Evangelista; and Bonnie Anderson and Judy Perkins as 2025 Grassroots Advocacy Award Honorees. Here are some photo highlights!

58 years of life with metastatic breast cancer in this photo—made possible by public investment in cancer research. Now we’re tossing future progress down the drain with federal research cuts. 😢 #NBCCSummit #NBCConTheHill #BecauseScience

Paolo Tarantino I don’t know that you can say that Destiny Breast 09 is practice changing. A lot of us are much more interested in a DEMETER approach with T’Dxd x6 followed by maintenance. Indefinite T’Dxd from the moment of diagnosis is a big pill to swallow and not patient friendly.

Julia Maués National Breast Cancer Coalition We have taken down the paywall on this article. Thank you for bringing it to our attention.

Huge news. New version of ESMO-MCBS is out! Introducing ESMO-MCBS v 2.0 with 13 new updates! Check it out today. Congratulations to the ESMO - Eur. Oncology -MCBS working group for the continued efforts to improve the tool and make it relevant and more valid. annalsofoncology.org/article/S0923-…

See you there today evening!

Congratulation Enrique Soto!!!! That is fantastic news for underrepresented people with breast cancer!

This discussion of SERENA-6 trial was excellent. #ASCO25 This doesn’t feel practice changing to me.

Nice slides to show issues and what to do on Monday morning-with Serena 6 data ASCO OncoAlert #ASCO25

I am loving Dr. DeMichele’s comments, including her insistence on longer survival and discussion of crossover issues. #ASCO25 #plenary #serena-6 Also loving audience questions. They are asking hard questions on the utility of PFS. I feel happy that the education is spreading and

The most impressive data of the day:

"Overall survival & quality of life superiority in modern phase Ill oncology trials." Phase Ill onc RCTs are commonly called "positive." But this is usually based on alternative endpoint improvement. Gains in either OS or QOL are uncommon, & exceedingly rare in combo. #ASCO25

Bishal Gyawali, MD, PhD, FASCO They should have used he Guidance for Discussants! ejcancer.com/article/S0959-…

Indeed. TBH, the discussant of the Serena 6 trial seemed to have hit most of the points of the checklist. Matterhorn on the other hand is a completely different story.